Scientific Advisory Board
The Clinical and Scientific Advisory Board (CSAB) comprises internationally renowned scientific and clinical advisors in the fields of diabetes and obesity, cardiology and gastroenterology to reflect the therapeutic focus of Zealand’s research and development activities.
The main objectives for the board are to:
Provide a forum for a continuously objective evaluation of Zealand’s applied scientific methods in peptide drug discovery and development as well as the company’s preclinical and clinical pipeline programs. The CSAB will evaluate best practices within R&D processes and challenge the science and development strategy of key projects.
Contribute cutting-edge scientific and clinical input tailored to Zealand’s therapeutic focus areas: diabetes, metabolic and other related diseases, including cardiovascular and gastrointestinal disorders.
Dr. Alain Munoz will jointly chair the CSAB.
Dr. Alain Munoz is member of the Board of Zealand and Co-chairman of the CSAB
The inaugural members of the advisory board are:
Dr. Bernard Charbonnel
Dr. Bernard Charbonnel is one of Europe’s leading experts in the field of diabetes. He is currently Professor of Endocrinology and Metabolic Diseases at the University of Nantes, France. Additionally, Dr. Charbonnel is the Principal National Investigator and International Coordinator of several ongoing clinical trials in the area of diabetic medicine and was a member of the Executive Committee of the PROactive clinical trial.
Dr. Charbonnel’s research interests include strategies for optimizing the management of Type 1 and Type 2 diabetes, insulin treatment, prevention of cardiovascular complications associated with Type 2 diabetes and new treatments for Type 2 diabetes.
Also notably, Dr. Charbonnel is a former president of the French Diabetes Society and a former chairman of the French Diabetes Guidelines Committee. He has contributed to over 200 original scientific papers in the area of diabetic medicine.
Dr. Gert Van Assche
Dr. Gert Van Assche is a renowned gastroenterologist, and Professor of Medicine at the University of Leuven, Belgium. Since 2000, he has been a clinical staff member of the Division of Gastroenterology at the University of Leuven Hospital.
Dr. Van Assche’s primary research focus is on novel therapies in fibro genesis and mucosal immunology in the field of Inflammatory Bowel Disease.
Dr. Van Assche received his medical degree from the University of Leuven in 1992. Dr. Van Assche has extensive experience as an advisor and consultant to the pharmaceutical industry in the gastro-intestinal field owing to his diverse clinical experience.
Dr. Åke Lernmark
Dr. Åke Lernmark is an expert and pioneer in the field of Type 1 diabetes research. He is Professor of Experimental Diabetes at Lund University in Malmö, Sweden as well as Professor Emeritus of Medicine at the University of Washington, Seattle
Dr. Lernmark’s research interests focus on the etiology and pathogenesis of Type 1 diabetes, the molecular genetics of islet autoimmunity and the molecular mechanisms of insulin secretion. He and his colleagues discovered GAD65 autoantibodies, one of the best predictive markers for Type 1 diabetes and also defined HLA-DQ as the major genetic risk factor for the disease. He is the principal investigator of clinical research studies to predict, prevent and intervene in Type 1 diabetes. He has published more than five hundred peer-reviewed articles in the field of endocrinology and autoimmune diabetes.
Dr. Lernmark received his medical degree from the Umeå University in Sweden in 1971.
Dr. Richard Pratley
Dr. Richard Pratley is an internationally recognized diabetes and obesity expert. Dr. Pratley is the Medical Director of the Florida Hospital Diabetes Institute, the largest endocrine practice in central Florida, and Senior Faculty at the hospital’s Sanford-Burnham Translational Research Institute for Metabolism and Diabetes. He is also a professor at the Sanford-Burnham Medical Research Institute at Lake Nona.
Dr. Pratley’s research interests include diabetes prevention and care improvement, drug research, innovation and development within the diabetes field; and understanding the role of the fat cell in potentiating diabetes and cardiovascular disease risk. Within these areas, Dr. Pratley has led a many large-scale investigations, including NIH- and pharmaceutical company-sponsored studies, about which he has published extensively.
Dr. Pratley graduated from Wayne State University School of Medicine, and is a member of the American Diabetes Association, the European Associations for the Study of Diabetes and The Obesity Society. He is a recipient of the Henry Christian Award for Excellence in Clinical Research from the American Federation for Clinical Research Foundation.
Dr. Paul Dorian
Dr. Paul Dorian is the Department Director for the University of Toronto’s Division of Cardiology as well as a Staff Electrophysiologist at St. Michael’s Hospital. Additionally, Dr. Dorian is Professor of Medicine in the University of Toronto’s Division of Cardiology and the Division of Clinical Pharmacology.
Dr. Dorian’s main areas of interest include research in advanced cardiac life support and clinical research in the pharmacology of cardiovascular drugs; implanted devices, and quality of life in patients with cardiovascular disease.
Dr. Dorian is a graduate of the McGill University Faculty of Medicine in Montreal. He currently serves as a Co-Principal Investigator on the NIH funded Resuscitation Outcomes Consortium, and as Chair of the arrhythmia section of the CaNNECTIN Canadian cardiovascular clinical trials collaborative, and is also part of the steering committee of several multicenter clinical trials in arrhythmia care.